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Abstract: Small molecule azobenzene derivatives are ubiquitous compounds and include synthetic 
dyes used in the food and textile industry, prodrugs for IBD and antibiotic treatment, and many 
natural compounds. The human azoreductases hNQO1 and hNQO2 have no activity with these 
substrates, so in vivo processing is entirely reliant on microbial azoreductases (AzoRs) found in 
the gut. In this investigation we seek to examine the substrate specificity of Class I AzoRs, an 
effect we expect is driven primarily through steric preferences. We hypothesize that structural 
subclasses of Class I AzoRs categorized by sequence homology and structural differences will 
demonstrate differential activities with distinct small-molecule substrates. To begin, we propose a 
robust methodology for identifying Class I azoreductases through key conserved residues. Using 
these residues, we identified 215 putative AzoRs from the Integrated Genome Catalog using 12 
query sequences of characterized Class I AzoRs. From these novel, putative AzoRs, four were 
selected for purification and characterization. To demonstrate substrate specificity, the catalytic 
efficiencies of a panel of the four novel Class I AzoRs, two previously characterized Class I AzoRs, 
and one representative Class II AzoR with several different Azo dyes was determined. Additional 
catalytic efficiencies of one AzoR with four key drug targets were also obtained. Finally, crystal 
structures of one of the novel AzoRs obtained both apo and with FMN cofactor bound were used 
with the kinetic and phylogenetic results to inform Class I subclasses with different predicted 
activities based on substrate. Understanding AzoR substrate specificity is critical to both industrial 
and biologic application, specifically dye-runoff detoxification and improving efficacy of azo-
linked 5-ASA IBD treatment.  
 
I. Introduction 
Azobenzene reductases, simply azoreductases or AzoRs, are a range of prokaryotic and 
eukaryotic enzymes that cleave the azo moiety R1-N=N-R2, where R1 and R2 represent aromatic 
groups. This Azo linkage is found in a diverse array of natural and synthetic compounds. Azo dyes 
are a group of synthetic pigments including the indicator Methyl Red and the carcinogenic Sudan 
Dyes.1 Most current bacterial azoreductase research has focused on using bacterial AzoRs to 
degrade azo dyes from textile mills to prevent human toxicity in the water supply. Strikingly, Azo-
linked pigments are also used heavily in the food industry, in which 65% of globally used synthetic 
food pigments are azo-based.2 This prevalence has caused concern for some, as azo food pigments 
have been linked to neurotoxic, genotoxic, and carcinogenic cellular effects.3,4 As such, restrictions 
have been imposed on the use of azo dyes in food in some countries, such as the FDA’s prohibition 
on the use of synthetic Amaranth in food items (a prohibition not shared by the UK, where it is 
still used to give candied fruits a red color). In nature, over 120 unique azo compounds found in 
plants, fungi, marine invertebrates, and bacteria have been predicted to have a wide range of 
antiviral, antibacterial, and anticancer activities, constituting a promising region of 
pharmacological exploration.5 Synthetically produced azo compounds have selective 
antimicrobial activity against gram-positive bacteria, including Staphylococcus aureus.6 
Moreover, as the azo linkage is used as a prodrug delivery method, azo compounds are already an 
important class of drugs. For example, prodrugs of 5-aminosalicylic acid, a drug used to treat IBD, 
as well as nitrofuran antibiotics, use a delivery method that requires processing by 
azoreductases.7,8,9 Azoreductase activity is not entirely limited to azo linkages, however. Indeed, 
select azoreductases have nitro-reductase and quinone-oxioreductase capacities as well, greatly 
expanding their possible physiological roles.10  
3 
 
While the known human azoreductases hNQO1/2 has been studied 
for decades, the study of bacterial AzoRs is a relatively new field originating 
in the late 1990s. Microbial AzoRs can be divided into four broad classes. 
Class I azoreductases, best represented by the E. coli AzoR1 (ecAzoRA), are 
FMN-dependent, oxygen insensitive, utilize NADH as a hydride source 
(although some are equally capable of using NADPH), and oligomerize as 
dimers or tetramers. The bi-bi-ping-pong mechanism for these AzoRs is well 
characterized as shown in Figure 1. For azo-reduction to occur, NADH is 
recruited into the active site, where it transfers a hydride onto the FMN flavin 
ring. NAD+ leaves the active site and the hydride is used to reduce the azobenzene substrate to the 
hydrazo-intermediate. The process repeats itself yielding two primary amine products. Class II 
azoreductases, those like Bacillus subtilis strain ISW1214 AzoR (bsAzoR), are FMN-dependent, 
oxygen insensitive, use NADPH as a hydride source, and oligomerize as either dimers or 
tetramers.11 One strictly anaerobic azoreductase has been characterized in the literature from 
Clostridium perfringens (cpAzoR).12 Although it shares above 20% sequence similarity with the 
Class II AzoRs, there are key differences that prevent falling into this family: cpAzoR is a trimer 
that uses FAD as a cofactor and shows preference for NADH as a hydride source.12 The final class 
of AzoRs are the flavin-free azoreductases, of which two have been classified from Xenophilus 
azovorans and Pigmentiphaga kullae. Both of these azoreductases are monomers and show little 
preference in electron source.13 Two additional enzymes previously characterized as triphenyl 
methane reductases were shown to have azo-reducing capacity; however, while homology 
suggests these enzymes are flavin free, there is no biochemical proof yet.However, a recent 
Fig. 1 Class I azoreduction 
mechanism 




publication from Zimmerman, et. al. challenges the current azoreductase status quo. The group 
identified two putative azoreducatases from Bacteroides thetaiotaomicron, labeled BT_0217 and 
BT_1429 through classical azide-cleavage processing of the 5-ASA derivative sulfasalazine.14 
Moreover, the group identified 3 serine-hydrolases from the same bacterium—BT_0569, 
BT_4096, and BT_0512—which also were capable of processing sulfasalazine.14 Figure 2 shows 
a phylogenetic tree with representatives from the traditional AzoR classes as well as the putative 
AzoRs from B. thetaiotaomicron. None of the new enzymes show any significant (above 20%) 
sequence similarity with any known azoreductases nor any significant sequence alignments. 
Understanding the differential processing capabilities amongst the diversity of 
azoreductases is of crucial importance, especially concerning IBD treatment, as show in Figure 3. 
Azo-linked 5-ASA treatments such as sulfasalazine are entirely reliant on processing by the drug 
microbiome for their activity, as the human azoreductase has no activity against small-molecule 
substrates. Moreover, these drugs must be taken in large, gram-scale quantities due to low 
bioavailability in the target intestines. For example, FDA data shows that while 85% of the initial 
prodrug is processed by gut bacteria, only 10 to 30% of the 5-ASA from sulfasalazine is absorbed 
by the intestinal lining.15 The excess of both the linked form of the drug and the 5-ASA metabolite 
have been further linked to nephritis in up to 1 in 100 patients, with clinically significant damage 
occurring in 1 in 500.16 More efficient processing by the gut microbiome could help reduce dose-
size and mitigate the amount of both linked drug and active metabolite that reaches the kidneys.  
Here, we seek to demonstrate differential substrate processing by azoreductases within the 
well-characterized family of the Class I enzymes using bioinformatic, structural, and kinetic 
analysis. We hypothesize that different Class I AzoRs, categorized into subclasses informed by 
sequence and structural homologies, will demonstrate significantly different activity with a group 
of small-molecule substrates. Using conserved residues, we propose a methodology for quickly 
identifying putative Class I AzoRs in gut metagenomes. Applying this rubric, we identify 215 
unique Class I AzoR sequences in the Integrated Gene Catalog. Of these enzymes, four novel Class 
I AzoRs are purified and their activities are characterized with a variety of substrates. We then 
compare their activity to two previously characterized Class I AzoRs and a representative Class II 
AzoR. Additional kinetic analyses of one Class I AzoR with pharmacologically relevant substrates 
are also presented. Finally, crystal structures both apo and with FMN cofactor bound are presented 
Fig. 3 Microbial role in Sulfasalazine (SSZ) bioactivity in the human gut 
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for one of the novel Class I AzoRs. By tying differences in catalytic efficiency to structural motifs, 




Materials Reagents were purchased from Tokyo Chemical Industry or Millipore Sigma. Genes for 
the seven tested azoreductases were ordered through Biobasic.  
Bioinformatic Analysis From the literature, the genomes of 11 characterized azoreductases were 
chosen to build the rubric. Aligning these sequences, 8 key conserved residues were identified, of 
which the 4 that were most directly located within the active site were chosen as the basis for the 
rubric (Figure 4). The rubric was then applied to the Human Microbiome Project database using 
EcAzoRA as the query sequence.17 Using these results, the rubric was refined to 12 query 
sequences and applied to the Integrated Gene Catalog, yielding a total of 215 putative Class I 
azoreductase sequences.18 These sequences were analyzed to generate a sequence similarity 
network using the EFI-EST tool.19 Examining these groupings, four novel Class I azoreductases 
were selected for more detailed kinetic and structural analysis. 
Protein Expression The signal peptide sequences were removed and AzoR genes with a N-terminal 
poly-his tag were transformed with heat shock into E. coli BL21Gold cells. After incubation at 37° 
C for 1 hour with shaking in LB, cells were centrifuged then plated onto LB + Ampicillin agar 
plates. Cultures were grown overnight at 37° C prior to harvesting. Colonies were selected and 
then grown overnight in LB broth overnight with shaking at 37° C. Subsequently, the broth culture 
was added to LB broth in a Fernbach culture flask with ampicillin and further grown with shaking 
and incubation at 37° C. Once the culture reached an optical density of 0.6 at 600 nm, the reaction 
culture was cooled to 18° C and IPTG was added to induce protein expression overnight. Cells 
were harvested by centrifuging the broth culture at 4500 RPM, resuspending the pellet, and then 
centrifuging again at 5000 RPM. The supernatant was discarded and the cells frozen for storage at 
-80° C. 
Protein Purification Cells were retrieved from -80° C storage and resuspended in NiA buffer with 
lysozyme and protease inhibitor. The resulting solution was sonicated and then centrifuged at 
18000 RPM. The cell lysate was then filtered and prepped to be loaded onto the Ni-affinity column. 
All proteins were expressed with a N-terminal 6x histidine tag and purified using a Ni-NTA HP 
column supplied from GE healthcare. Fractions containing the protein of interest were equilibrated 
using a HiLoad 16/60 Superdex 200 gel filtration column. Protein fractions were collected and 
concentration was determined by absorbance at 280 nm using predicted molecular weights and 
molar extinction coefficients. Aliquots of protein were flash frozen in liquid nitrogen and stored 
at -80° C until use in crystallography or assays. 
CmAzoR Crystallography Apo crystals of CmAzoR were obtained via the hanging-drop vapor 
diffusion method. Mother liquor consisted of 0.1 M HEPES pH 7.5 and 30% PEG 8000. 
Diffraction data for the crystals was obtained on the 23-ID-B beamline at GM-Ca-CAT (Advanced 
Photon Source, Argonne National Laboratory). CCP4i was used to scale the raw data, and Phenix 
was used to refine the model.  
Fig. 4 EcAzoRA sequence with conserved rubric residues in blue and other conserved residues in red. 
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Kinetic Assays Absorbance assays were conducted with UV-vis detection at 37 °C. Initial 
conditions were 1 mM NAD(P)H cofactor, 20 mM pH 8.0 Tris-HCL buffer, 500 nM enzyme, and 
substrate concentrations were varied from 20-50 μM. For kinetic assays of olsalazine, balsalzide, 
and nitrofurantoin, 500 µM NADH was used with drug concentrations ranging from 50-150 µM. 
Total reaction volume was 200 μL. For drug substrates, absorbance was recorded at 410 nm while 
absorbance for the dyes was tracked at the wavelength of maximum absorption. Reactions were 
incubated at a temperature 37 °C for ten minutes prior to analysis. For methyl red, final well 
concentration of DMSO was 5%. Prior to addition to the reaction mixture, enzyme was incubated 
on ice with excess FMN for 10 minutes. Absorbance scans of the enzyme and NADH were taken 
to confirm no significant absorbance at 410 nm. After a minimum ten minutes of reaction progress, 
recording ceased and initial reaction velocities for each substrate concentration were determined. 
These velocities were transformed into apparent kcat values, the slope of which versus substrate 
concentration yielded a ready approximation of catalytic efficiency (kcat/KM). HPLC assays were 
conducted for Sulfasalazine with the same concentrations and volumes as the absorbance protocol 
for drug substrates. Quenches were done at 5-minute intervals using 50 μL 5% TFA with a total 
reaction time of 20 minutes. 80 μL from each well were then centrifuged for 15 minutes at 1300 
rpm. The HPLC analysis used two mobile phases with a 5 μL injection volume. Mobile phase A 
was 10 mM ammonium acetate and 0.1% formic acid in water. Mobile phase B was 10 mM 
ammonium acetate and 0.1% formic acid in methanol. Elution was 10-95-95-10% mobile phase B 
as a percentage of A, with timing of 0, 10, 15, and 15.1 minutes for the changes. Absorbance was 
detected at 358 nm. 
 
III. Results and Discussion 
The sequence similarity network generated using the 215 AzoRs identified from the 
Integrated Gene Catalog is shown in Figure 5. It is evident from the network that the diversity of 
Class I AzoRs has yet to be explored in the literature, as the majority of studied AzoRs are clustered 
with EcAzoRA. We identify a large cluster of Class I AzoRs remotely connected to and larger than 
the EcAzoRA cluster that remains relatively unexplored. From this cluster, we selected the first 
enzyme for analysis, the putative AzoR from Clostridium sp. Marseille-P7770 (CmAzoR). Three 
Fig. 5 Sequence Similarity Network of the IGC Class I AzoRs. Class I AzoRs used as query sequences are shown in brown, 
enzymes selected for kinetic analysis are shown in dark blue and labeled. Each node represents sequences with 90% identity 
-log(E) = 30 
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additional putative AzoRs were selected from the following species: Bacteroides cellulosilyticus 
(BcAzoR), Odoribacter splanchnicus (OsAzoR), and an additional azoreductase from E. coli 
(EcAzoRB). As standards for comparison the characterized Class I AzoR from Klebsiella 
pneumoniae (KpAzoR), EcAzoRA, and a characterized Class II AzoR from Staphylococcus aureus 
(saAzoR) were also selected for kinetic analysis. The alignment of the query sequences and 
selected novel AzoRs is shown in Figure 6. Several structural motifs appear to be conserved. At 
the conserved ecAzoRA P95 there is a sequence that usually contains an aromatic residue as well 
as an asparagine or aspartic acid that binds the flavin ring of the FMN cofactor. Another conserved 
motif begins at EcAzoRA T118, where there is a TF_Y/F motif in the active site top loop. The 
second aromatic points directly into the Class I active site and may be involved in recruiting 
substrates. The final key conserved residues are the two glycine residues at EcAzoRA G142 and 
G143, which have been indicated to be key residues in providing the structural flexibility necessary 
to facilitate NAD(P)H binding.20 From the alignment, BcAzoR and OsAzoR seem to have 
unorthodox structural features, as BcAzoR has a histidine in the active site top loop (TFRH) and 
OsAzoR seems to lack an aligned top loop sequence entirely. Moreover, both enzymes have 
aromatic-heavy FMN binding sequences, missing the traditional N/D at EcAzoRA N98.  
  
Fig. 6 Alignment of Class I azoreductases with consensus sequence (threshold >80%). 1 is OsAzoR, 2 is CmAzoR, 3 is 
BcAzoR, 4 is EcAzoRA, 5 is EcAzoRB, 6 is KpAzoR, and 7-17 are additional literature Class I AzoRs used in the IGC rubric 
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 Catalytic efficiencies for the enzyme panel against the common AzoR reporter substrate, 
































Fig. 7 Catalytic efficiencies of the enzyme panel with methyl red. Error bars are standard error, and asterisks indicate significance 


































Fig. 8 Catalytic efficiencies of the enzyme panel with amaranth. Error bars are standard error, and asterisks indicate significance level 
when compared to EcAzoRA (**** = 0.001, *** = 0.01, ** = 0.05, * = 0.10). 
9 
 
both NADH and NADPH. All the Class I AzoRs showed either a preference for NADH as a 
hydride source, or indifference (catalytic efficiencies were statistically indistinguishable) between 
the cofactors as predicted by the literature Class I definition. SaAzoR only showed activity with 
NADPH, confirming the literature result as well. It is readily apparent that EcAzoRA is by far the 
most active enzyme with methyl red, with BcAzoR’s activity placing solidly second. In 
comparison to these enzymes, catalytic efficiencies for the other five enzymes in the panel are ten 
to a hundredfold less. While all enzymes showed some activity with methyl red with at least one 
hydride source, this wide range of observed catalytic efficiencies suggests that methyl red may not 
be a reliable reporter substrate. A reporter substrate with less variable processing could be more 
informative for future investigations. 
 Continuing, Figure 8 summarizes catalytic efficiencies for the enzyme panel with synthetic 
amaranth (alternatively known as Acid Red 27, FD&C Red No. 2). For this assay, only the favored 
cofactor was used (NADH for the Class I AzoRs and NADPH for SaAzoR). Once again, 
significant differences in activity are seen between enzymes. OsAzoR and SaAzoR showed 
relatively reduced activity with the substrate, while EcAzoRA, KpAzoR, and CmAzor showed 
greater activity. Unlike with methyl red, EcAzoRA was not the most active enzyme with amaranth. 
Instead, CmAzoR had the highest value of the catalytic efficiency, notable as CmAzoR had one of 
the lowest catalytic efficiencies with methyl red. Notably, while CmAzoR had the largest catalytic 























Fig. 10 KpAzoR catalytic efficiency with a variety of drug substrates. Error bars represent standard error. 
10 
 
efficiency of any enzyme in the panel with amaranth dye, the magnitude of this value was only 
one tenth of the EcAzoRA and methyl red reaction. Thus, these data provide support for our 
hypothesis: different enzymes show statistically significant differences in activity with different 
sizes of substrate. These differences can be further visualized using the heatmap in Figure 9 (data 
for Acid Orange 7 and Brilliant Black forthcoming).  
To see if differences in substrate processing extend into AzoR processing of key drug 
substrates, catalytic efficiencies for KpAzoR with the IBD drugs olsalazine, sulfasalazine, and 
balsalazide as well was with the antibiotic nitrofurantoin were determined as showing in Figure 
10. No significant differences in catalytic activity can be seen between the three IBD drugs. This 
may suggest that in KpAzoR, the conserved 5-ASA active moiety interacts with the active site the 
most, meaning that the three prodrugs have similar active site affinity. KpAzoR activity is 
significantly higher with nitrofurantoin, once again suggesting that different substrates are 
processed preferentially by different enzymes. Kinetic analysis of other enzymes with these 
substrates may confirm this differential processing. 
CmAzoR was less active with methyl red than with amaranth, while EcAzoRA was 
significantly more active than any other enzyme with methyl red and less active than CmAzoR 
with amaranth. Structural analysis may give insight. Figure 11 shows the apo crystal structure of 
CmAzoR, the FMN-bound crystal structure, and the alignment of the two. While Figure 11 
presents these structures as monomers, the crystal structure reveals CmAzoR to be a homodimer. 
Resolution of the second alpha helix is greatly increased in the FMN bound structure, perhaps 
indicating the key role this cofactor takes in stabilizing the overall structure of the enzyme. Figure 
12 presents the FMN-bound homodimer. 
 Figure 13 shows a focused view of the active site of the enzyme at the dimeric interface, 
with key residues shown. W91 is likely the key residue in securing the flavin-ring through pi-pi 
stacking interactions. The E59 and R63 sit on the alpha helix at the active site pocket, and these 
charged residues may interact with substrates. D172 at the mouth of the active site sits on a flexible 
loop nearby the NADH G119-G120 binding motif and may also be involved in substrate binding. 
Finally, the Class-I-conserved F115 likely plays a role in aromatic pi-pi stacking with substrates 
in the active site.  
 Examining Figure 12 and Figure 13 it becomes readily apparent something is amiss in the 
active site. The green sequence in the figure is the sequence leading up to the un-cleaved N-
terminal poly-his tag. The phenylalanine and tyrosine of the poly-his tag sequence of an adjacent 
monomer not part of the homodimer engages in stable pi-pi stacking in the active site, excluding 
other substrates in attempted crystallography (such as methyl red). Fortunately, at the dilute 500 
nM assay enzyme concentration, we can assume this un-cleaved his-tag should have relatively 
little effect on kinetic data (supporting data for this assumption forthcoming). However, for future 
crystallography efforts it will be necessary to cleave off the poly-his tag in order to crystalize 
CmAzoR with a substrate or inhibitor bound.  
 Connecting the structural data to the activity data, Figure 14 overlays the literature 
EcAzoRA structure with CmAzoR. While the top loop and FMN-binding motif do not appear 
dramatically different, there are key distinctions between the mouth and active site pocket of the 
two enzymes, and the FMN positioning of both enzymes is nearly identical. While the active site 
pocket helix of CmAzoR is charged with E59 and R63, the active site of pocket helix of EcAzoRA 
is lined with small nonpolar residues such as V56 as shown. At the active site entrance, H144 and 
Y176 sit on flexible loops may be involved in substrate recruitment for EcAzoRA. This aromaticity 
is entirely lacking from active site entrance of CmAzoR. Methyl red is small and relatively 
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nonpolar while synthetic amaranth is slightly large and has negative charges at is ends due to the 
sulfate groups. The aromatic and nonpolar residues of the EcAzoRA active site may effectively 
recruit FMN, while the bulkier, charge Amaranth is less efficiently attracted. The charged residues 
in the CmAzoR active site may give that enzyme slightly more efficiency that EcAzoRA in binding 
amaranth dye. Similarly, the lack of recruiting aromatic groups at the active site entrance of 
CmAzoR and polar active site may explain its inefficiency in processing methyl red as compared 
to the other Class I enzymes.  
 Thus, in the construction of Class I AzoR subclasses special care should be given to the 
active site pocket helix residues and flexible loop recruiting residues, as these distinctions may 
serve to explain activity differences between EcAzoRA and CmAzoR. Structures of OsAzoR and 









IV. Conclusion and Future Directions 
Both kinetic and structural results support our hypothesis that Class I AzoRs exhibit 
differential processing of azo substrates, and that this differential processing stems from structural 
differences at the active site. These distinctions can be developed into activity-informed subclasses 






Fig. 13 CmAzoR Active site. Each monomer appears in a different shade of gray. The FMN appears in yellow. The key 
active site residues are labeled and appear in indigo. The interfering poly-his tag sequence appears in green. 
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of Class I AzoRs. Differential processing was seen with both dye and drug substrates. From a 
bioinformatic standpoint, the sequence similarity alignment has revealed that there are vast swaths 
of Class I AzoR biodiversity that are relatively unexplored. Importantly, this study has focused 
only on Class I AzoRs. Class II, anaerobic, and flavin-free AzoRs may also be playing important 
roles in the gut microbiome and exhibiting such differential processing. Indeed, the data from 
Zimmerman’s study of B. thetaiotaomicron suggests that AzoR diversity may expand beyond these 
four traditional classifications. As these microbial AzoRs are the human body’s only processor of 
small-molecule azo compounds, understanding how structure influences function for these 
enzymes is critical. The many roles azo compounds take in the body, from carcinogenic dyes to 
naturally occurring antibiotics to IBD prodrugs, only make further exploration of AzoRs more 
important.  
 Moving forward, a similar top-down bioinformatic, kinetic, and structural approach should 
be taken for the Class II enzymes. The existing Class I enzyme panel should also be expanded to 
include different clusters found in the SSN. Additionally, more enzymes should be tested with 
clinically relevant substrates. Broadly, continuing to pursue novel structures will yield further 






Fig. 14 Alignment of the EcAzoRA (2Z9C) and CmAzoR active sites. CmAzoR monomers appear in two different shades of 
gray. EcAzoRA appears in green. FMN appears in yellow sticks for CmAzoR, and yellow lines for EcAzoRA. Key resides for 
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